Kazia Therapeutics
KZIA
8 hedge funds and large institutions have $568K invested in Kazia Therapeutics in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
75% more capital invested
Capital invested by funds: $324K → $568K (+$244K)
14% more funds holding
Funds holding: 7 → 8 (+1)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HAG
HighPoint Advisor Group
Downers Grove,
Illinois
|
+$88.8K |
| 2 |
Morgan Stanley
New York
|
+$6.02K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$20.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.78K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $251K | +$6.02K | +44 | +3% |
|
2
Renaissance Technologies
New York
| $129K | – | – | – |
|
|
HAG
3
HighPoint Advisor Group
Downers Grove,
Illinois
| $96K | +$88.8K | +649 | New |
|
|
4
Citadel Advisors
Miami,
Florida
| $49K | -$20.9K | -153 | -37% |
|
|
TW
5
Transform Wealth
Greenwood Village,
Colorado
| $41K | – | – | – |
|
|
SPIA
6
Steward Partners Investment Advisory
New York
| $2K | – | – | – |
|
|
RE
7
RBC Europe
London,
United Kingdom
| $120 | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$1.78K | -13 | -87% |
|
KZIA Hedge Fund Activity: Q3 2019 in Review
8 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q3 2019, worth a combined $568K — up 75% from $324K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new KZIA positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was HighPoint Advisor Group, opening a new position worth an estimated $88.8K. The largest seller was Citadel Advisors, cutting an estimated $20.9K.
- 8 institutional investors held Kazia Therapeutics (KZIA) as of Q3 2019, up from 7 in Q2 2019.
- Funds reported $568K of Kazia Therapeutics stock for Q3 2019, up 75% quarter-over-quarter.
- 1 fund opened new Kazia Therapeutics positions in Q3 2019 and 0 closed out, a net change of +1 holder.
- The largest Kazia Therapeutics buyer in Q3 2019 was HighPoint Advisor Group, an estimated $88.8K added.
- The largest Kazia Therapeutics seller in Q3 2019 was Citadel Advisors, an estimated $20.9K sold.
Based on aggregated 13F filings for Q3 2019.